The 1st Asia Pacific Congress on
Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
Shanghai, China, June 2-5, 2011 |
|
| |
| Saturday June 4, 2011 |
 |
|
|
|
HALL A |
|
|
Session 14
PREVENTION OF DIABETES |
|
|
8:30-8:35 Chairpersons: B. Itzhak, Israel & A. El-Sayed, Egypt
8:35-8:55 Score for high risk in Diabetes in Asia G. Ning, China
8:55-9:15 High prevalence in the Gulf region A. El-Sayed, Egypt
9:15-9:35 Difference in candidate gene for T2D in Asia Y.S. Cho, Korea
9:35-10:00 Discussion |
|
10:00-10:30 |
Coffee Break |
|
|
Session 15
WHAT IS OF SPECIAL IMPORTANCE FOR HYPERTENSION AND ITS TREATMENT IN ASIA? |
|
|
10:30-10:35 Chairpersons: P.M. Nilsson, Sweden & J. Wang, China
10:35-10:50 The epidemiological perspectives for populations in transition P.M. Nilsson, Sweden
10:50-11:05 Stroke more important than CHD in Asian countries: Still true? K. Kario, Japan
11:05-11:20 A review of interventions studies including Asian patients with hypertension X. Du, China
11:20-11:35 Which antihypertensive drugs to prefer in Asian patients? J. Wang, China
11:35-12:00 Discussion |
|
12:00-12:10 |
Technical Break |
|
|
Session 16
MEET THE PROFESSOR |
|
12:10-12:15 Chairperson: A. Rubinstein, Israel
12:15-12:30 Beta cell function and diabetes in China W. Yang, China
Oral Presentations
12:30-12:45 High serum IgA concentrations and risks of impaired fasting glucose, hypertension, and hypercholesterol among children
C.C. Liao, Taiwan, F.C. Sung, T.C. Su, K.L. Chien, Y.T. Lee
12:45-13:00 Diabetes complications and BMI in Asia, Africa, Europe, and Latin America: A1chieve baseline data
W. Yang, China, G. Gonzalez-Galvez, P. Home, I.M. Hajjaji, P.N. Chakkarwar, P. Soewondo |
|
13:00-14:00 |
Lunch Break |
|
|
Session 17
FDA CARDIOVASCULAR ASSESSMENT REQUIREMENTS: IMPLICATIONS FOR CLINICAL RESEARCH IN CHINA |
|
14:00-14:05 Chairpersons: B. Hirshberg, USA & J. Zhao, USA
14:05-14:20 Impact of the US FDA cardiovascular assessment requirements on the development of novel antidiabetes drugs B. Hirshberg, USA
14:20-14:40 The China KOL's perspective L. Ji, China
14:40-15:00 Global CV outcome studies, view point of the Chinese regulatory authority Z. Yang, China
15:00-15:30 Discussion |
|
15:30-16:00 |
Coffee Break |
|
|
Session 18
INDIVIDUALISED THERAPY IN ASIAN T2D PATIENTS |
|
16:00-16:05 Chairperson: M. Hanefeld, Germany
Are all Asian patients the same when it comes to diabetes?
Case reports:
16:05-16:25 Germany vs. Japan M. Hanefeld, Germany
16:25-16:45 India A. Kumar, India
16:45-17:05 Cambodia L. Keuky, Cambodia
17:05-17:30 Discussion |
|
HALL B |
|
|
Session 19
EXTRA GLYCAEMIC EFFECTS OF INCRETIN BASED THERAPY IN T2D |
|
8:30-8:35 Chairperson: S. Del Prato, Italy
8:35-8:55 The heart S. Del Prato, Italy
8:55-9:15 The brain J. Davidson, USA
9:15-9:35 The vascular system O. Mosenzon Israel
9:35-10:00 Discussion |
|
10:00-10:30 |
Coffee Break |
|
|
Session 20
TREATMENT GOALS IN DIABETES |
|
10:30-10:35 Chairpersons: E. Standl, Germany & K. Abdul Kadir, Malaysia
Should we aim to normalise A1c?
10:35-10:50 Pro: E. Standl, Germany
10:50-11:05 Con: K. Abdul Kadir, Malaysia
Drug therapy for Prediabetes:
11:05-11:35 Yes: K.H. Yoon, Korea
11:35-12:00 Discussion |
|
12:00-12:10 |
Technical Break |
|
|
Session 21
ORAL PRESENTATIONS |
|
12:10-12:20 Chairperson: I. Raz, Israel
12:20-12:30 Validity of dietary glycemic load as a predictor of postprandial glycemia and insulinemia in lean, young healthy adults
J. Bao, Australia, F. Atkinson, P. Petocz, W. Willett, J. Brand-Miller
12:30-12:40 Cut-off value of 50-gram glucose challenge test for the diagnosis of gestitational Diabetes Mellitus
D. Boriboonhirunsarn, Thailand, T. Lertbunnaphong, P. Khanmali
12:40-12:50 The ratio of leg-length over standing height as a predictor of childhood obesity: Results from a longitudinal cohort study
J. Liu, Canada, N. Akseer, B. Faught, J. Hay, J. Cairney
12:50-13:00 The outcome of Beta cell function after early insulin therapy in teh recently diagnosed Type 2 Diabetes (in Egyptian population) our experience in El-Minia University Hospital
Y.M. Mosa, A.M. Mohamed, S.H. El Hini, M.S. Kamel, Egypt, A.S. Salama, G.M. El Sagheer, A.M. Osman |
|
13:00-14:00 |
Lunch Break |
|
|
Session 22
EVIDENCE FROM CLINICAL TRIALS IN DIABETES |
|
14:00-14:05 Chairperson: L. Van Gaal, Belgium
14:05-14:25 Specific OHG effects on CVD I. Raz, Israel
14:25-14:45 HDL: Unmet challenge L. Van Gaal, Belgium
14:45-15:05 Statin or combination O. Mosenzon, Israel
15:05-15:30 Discussion |
|
15:30-16:00 |
Coffee Break |
|
|
Session 23
|
|
16:00-16:05 Chairperson: P. Pozzilli, Italy
16:05-16:25 The increased incidence of Type 1 Diabetes (T1D) worldwide: What to blame? P. Pozzilli, Italy
16:25-16:45 Promising treatment to limit beta cell destruction J. Palmer, USA
16:45-17:05 Application of technology to the disease management R. Weiss, Israel
17:05-17:30 Discussion |
|
HALL C |
|
|
Session 24
HYPERTENSION |
|
8:30-8:35 Chairpersons: P.M. Nilsson, Sweden & J. Wang, China
The "Pearls and Perils" of managing hypertension in people with diabetes
8:35-8:50 Pearls: J. Wang, China
8:50-9:05 Perils: X. Du, China
9:05-9:25 ACEs or ARBs as first line treatment of hypertension in diabetes E. Imai, Japan
9:25-9:40 Are all RAAS blockers equal? P.M. Nilsson, Sweden
9:40-10:00 Discussion |
|
10:00-10:30 |
Coffee Break |
|
|
Session 25
SGLT2 INHIBITORS |
|
10:30-10:35: Chairperson: G. Schernthaner, Austria
10:35-11:00 The kidney and its role in glucose homeostasis J. Davidson, USA
11:00-11:25 Glucosuria as a novel approach in diabetes management G. Schernthaner, Austria
11:25-11:40 Clinical development of anti-diabetic agents in China X.H. Guo, China
11:40-11:55 Discussion
11:55-12:00 Closing Remarks G. Schernthaner, Austria |
|
12:00-12:10 |
Technical Break |
|
|
Session 26
ORAL PRESENTATIONS |
|
12:10-12:20 Chairperson: V. Hainer, Czech Republic
12:20-12:30 Cardiovascular safety of liraglitude: A pooled analysis from Phase II and III liraglutide clinical development studies
Y.Y. Huang, Taiwan, S.P. Marso, A.C. Moses, M.J. Zychma, J.B. Buse
12:30-12:40 Association of Paraoxonase 1 Gene polymorphism with Intima media thickness (IMT) of the Carotif arterise in Japaneses Type 2 Diabetic patients
I. Yamamoto, Japan, T. Honda, K. Takada, M. Maeda, S. Nonen, T. Motomura, K. Maeda, Y. Fujio, J. Azuma
12:40-12:50 Association of maternal CMI with adverse pregnancy outcomes- difference between South Asian, South East Asian and Australian women
N. Moin, Australia, S. Hendon, J. Bradford, P. Henriksson, M. McLean
12:50-13:00 Diabetes Mellitus following liver transplantation: Incidence, glucose monitoring and treatment options in single centre
I. Daskalova, Bulgaria, I. Takarov, E. Odisseeva, T. Lukanova, R. Velichkova, N. Vladov |
|
13:00-14:00 |
Lunch Break |
|
|
Session 27
CV RISK AND INSULIN RESISTANCE IN CHILDHOOD: THE ASIAN PERSPECTIVE |
|
14:00-14:05 Chairpersons: R. Weiss, Israel & W. Lee, Singapore
14:05-14:20 Melanocortin 3 receptor and Melanocortin 4 receptor genetic mutations: The Asian perspective Y.S. Lee, Singapore
14:20-14:35 Metabolic syndrome – Early life exposure W. Lee, Singapore
14:35-14:50 Obesity and metabolic syndrome in Chinese children H. Wang, China
14:50-15:05 Bariatric surgery for obese adolescents with related comorbidity R. Weiss, Israel
15:05-15:30 Discussion |
|
15:30-16:00 |
Coffee Break |
|
|
Session 28
BARIATRIC SURGERY IN OBESITY AND DIABETES IN ASIA |
|
16:00-16:05 Chairperson: G. Schernthaner, Austria
Last resort in obese patients
16:05-16:20 Pro: C.K. Huang, Taiwan
16:20-16:35 Con: V. Hainer, Czech Republic
Early in the obese patient with risk factors
16:35-16:50 Pro: S.K.H. Wong, China (HK)
16:50-17:05 Con: W.H-H. Sheu, Taiwan
17:05-17:30 Discussion |
|
|
|
|
WebStudio.co.il